As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
8 Analysts have issued a Angion Biomedica Corp forecast:
8 Analysts have issued a Angion Biomedica Corp forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -43 -43 |
8%
8%
|
|
| EBIT (Operating Income) EBIT | -45 -45 |
8%
8%
|
|
| Net Profit | -55 -55 |
41%
41%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.
| Head office | United States |
| CEO | Robert Connelly |
| Employees | 32 |
| Founded | 2011 |
| Website | elicio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


